

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8166603

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
AVALO THERAPEUTICS, INC.	09/13/2023
RECEIVING PARTY DATA	
Name:	HORIZON TECHNOLOGY FINANCE CORPORATION
Street Address:	312 FARMINGTON AVENUE
City:	FARMINGTON
State/Country:	CONNECTICUT
Postal Code:	06032
PROPERTY NUMBERS Total: 8	
Property Type	Number
Patent Number:	11708406
Patent Number:	10745435
Patent Number:	11479576
Application Number:	18329069
PCT Number:	US2022074106
PCT Number:	US2023060064
PCT Number:	US2022031332
Application Number:	18323488
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8602846434
Email:	nicole@horizontechfinance.com
Correspondent Name:	NICOLE PAPPA
Address Line 1:	312 FARMINGTON AVENUE
Address Line 4:	FARMINGTON, CONNECTICUT 06032
NAME OF SUBMITTER:	NICOLE PAPPA
SIGNATURE:	/s/ Nicole Pappa
DATE SIGNED:	09/14/2023

Total Attachments: 4

source=Grant of Security Interest Patents (Avalo) (executed)#page1.tif

source=Grant of Security Interest Patents (Avalo) (executed)#page2.tif

source=Grant of Security Interest Patents (Avalo) (executed)#page3.tif

source=Grant of Security Interest Patents (Avalo) (executed)#page4.tif

GRANT OF SECURITY INTEREST
PATENTS

THIS GRANT OF SECURITY INTEREST, dated as of September 13, 2023, is executed by AVALO THERAPEUTICS, INC., a Delaware corporation with an address of 540 Gaither Road, Suite 400, Rockville, MD 20850 ("Debtor"), in favor of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an address of 312 Farmington Avenue, Farmington, Connecticut 06032 ("Secured Party").

A. Pursuant to a certain Venture Loan and Security Agreement, dated as of June 4, 2021, as amended by that certain First Amendment to Venture Loan and Security Agreement, dated on or about the date hereof (as further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Agreement") by and among Debtor, the Secured Party and the lenders party thereto (the "Lenders"), the Lenders agreed to extend credit to Debtor upon the terms and subject to the conditions set forth therein;

B. Debtor owns the patents and/or applications for patents, more particularly described on Schedules 1-A and 1-B annexed hereto as part hereof (collectively, the "Patents");

C. Pursuant to the Agreement, Debtor has granted to Secured Party a security interest in all right, title and interest of Debtor in and to the Patents, together with any reissue, continuation, continuation-in-part or extension thereof, and all proceeds thereof, including any and all causes of action which may exist by reason of infringement thereof for the full term of the Patents (the "Collateral"), to secure the prompt payment, performance and observance of the Obligations (as defined in the Agreement);

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby further grant to Secured Party a security interest in the Collateral to secure the prompt payment, performance and observance of the Obligations.

Debtor does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

IN WITNESS WHEREOF, Debtor has caused this instrument to be executed as of the day and year first written above.

AVALO THERAPEUTICS, INC.

By: 

Name: GARY NEIL

Title: Chief Executive Officer

SCHEDULE 1-A TO GRANT OF SECURITY INTEREST

PATENTS

Patent	Owner	Registration Number	Registration Date
Method of Treating Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) Associate with COVID-19 by Administering an anti-LIGHT Antibody	Avalo Therapeutics, Inc.	US Patent No. 11,708,406	July 25, 2023
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	Australian Patent No. 2016355429	August 26, 2021
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	Japanese Patent No. 7019585	February 3, 2022
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	US Patent No. 10,745,435	August 18, 2020
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	US Patent No. 11,479,576	October 25, 2022

SCHEDULE 1-B TO GRANT OF SECURITY INTEREST

PATENT APPLICATIONS

Patent Application	Owner	Application Number	Application Date
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Australian Appln. No. 2021248833	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Brazilian Appln. No. BR112022019112-0	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Canadian Appln. No. 3173873	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Chinese Application No. 202180025379.X	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	European Appln. No. 21779221.7	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Japanese Appln. No. 2022-559844	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Korean Appln. No. 10-2022-7037145	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Mexican Appln. No. MX/a/2022/011811	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	Taiwanese Appln. No. 110112015	March 31, 2021
Methods and Treatment Involving Excess Free Light	Avalo Therapeutics, Inc.	US Appln. No. 18/329,069	March 31, 2021
Methods of Treating Ulcerative	Avalo	PCT/US2022/074106	July 25, 2022

Colitis with Anti-LIGHT Antibodies	Therapeutics, Inc.		
Methods of Treating Asthma with Anti-LIGHT Antibodies	Avalo Therapeutics, Inc.	PCT/US2023/060064	January 4, 2023
Methods and Treatment for Complex Lymphatic Malformations	Avalo Therapeutics, Inc.	PCT/US2022/031332	May 27, 2022
Methods and Treatment for Complex Lymphatic Malformations	Avalo Therapeutics, Inc.	US Appln. No. 18/323,488	May 25, 2023
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	Canadian Appln. No 3005444	May 15, 2018
Nucleic acid prodrugs	Avalo Therapeutics, Inc.	European Appln. No. 16867037.0	June 11, 2018